Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463267 | 0.71 | WDR5 (0.52) | NOTUMNPC1RAB9AKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL440262 | 0.70 | WDR5 (0.51) | NOTUMNPC1RAB9AKDM4EMAPT | |
| Biphenyl SCHEMBL7614586 | 0.69 | RAB9A (0.63) | NOTUMNPC1RAB9AAKR1C3AKR1C1 | |
| Biphenyl SCHEMBL7610874 | 0.69 | RAB9A (0.57) | NOTUMNPC1RAB9AAKR1C3AKR1C1 | |
| Biphenyl SCHEMBL7611759 | 0.69 | RAB9A (0.74) | NOTUMNPC1RAB9AAKR1C3AKR1C1 | |
| Biphenyl SCHEMBL11881576 | 0.69 | RAB9A (0.74) | NOTUMNPC1RAB9AAKR1C3AKR1C1 | |
| SCHEMBL8447696 | 0.68 | HTR2A (0.43) | NOTUMAKR1C3AKR1C1 | |
| SCHEMBL1126871 | 0.67 | WDR5 (0.47) | NPC1RAB9AKDM4EMAPTPKM | |
| Biphenyl SCHEMBL7615710 | 0.67 | RAB9A (0.55) | NPC1RAB9AAKR1C3AKR1C1 | |
| SCHEMBL942428 | 0.66 | KDM4E (0.45) | NPC1RAB9AKDM4EMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | NOTUM 255/4885NPC1 142/4885RAB9A 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.